TNGX — Tango Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $163.24m
- -$94.67m
- $42.07m
Annual income statement for Tango Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 37 | 24.9 | 36.5 | 42.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 0.181 | 95.2 | 136 | 151 | 188 |
| Operating Profit | -0.181 | -58.2 | -111 | -114 | -146 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.116 | -57.9 | -108 | -102 | -130 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.123 | -58.2 | -108 | -102 | -130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.123 | -58.2 | -108 | -102 | -130 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.123 | -58.2 | -108 | -102 | -130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.006 | -0.938 | -1.23 | -1.08 | -1.19 |
| Dividends per Share |